0RUG.LSE bioMerieux S.A.

Healthcare Commercial Services & Supplies London Exchange
- EUR
Market cap
-
P/E
-
P/B
-
ROE
-
Dividend yield
0.74%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2023.

Is 0RUG.LSE undervalued?

Graham number

The Graham number of bioMerieux S.A. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

bioMerieux S.A. fundamental analysis

No fundamental analysis for bioMerieux S.A. yet.

bioMerieux S.A. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About bioMerieux S.A.

bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; BACT/ALERT VIRTUO, a blood sample culture system; BIOFIRE, a multiplex polymeras…

Full company profile